Old 12-06-2018, 03:07 PM #1 (permalink)
lgelb's Avatar
Extremely Helpful Member

Forum Moderator
 
Join Date: 2009
City: Seattle
State: WA
Country: US
Diagnosed: 09/2009
Interest: I lost a loved one to ALS/MND.
Posts: 6,575
lgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond repute
♥ lgelb lgelb is offline
Extremely Helpful Member

Forum Moderator

lgelb's Avatar
Join Date: 2009
City: Seattle
State: WA
Country: US
Diagnosed: 09/2009
Interest: I lost a loved one to ALS/MND.
Posts: 6,575
lgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond reputelgelb has a reputation beyond repute
Default Biogen picks up Ionis SOD1 treatment option

This is important not just for advancing SOD1 tx, but establishing another case where a smaller firm (where a lot of ALS work is being done) has successfully handed off a therapy to a larger firm. This helps incentivize ALS research.

----
[Adapted from Seeking Alpha] Having seen positive early-stage data, Biogen has exercised its option to develop and commercialize Ionis Pharmaceuticals' IONIS-SOD1 rx (BIIB067) for the treatment of SOD1 mutations, representing ~2% of total ALS cases.

The action triggers a $35M milestone payment to Ionis, who is eligible for up to $55M in milestones and low-to-mid-teen royalties on net sales.
lgelb is offline   Reply With QuoteReply With Quote
The Following 4 Users Say Thank You to lgelb For This Useful Post:
Ash12345 (12-06-2018), dldugan (12-06-2018), KateEmerson (12-06-2018), vltsra (12-06-2018)
Reply

Tags
age, als, als research, biogen, data, early, milestone, research, sod1, therapy, treatment, work


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are Off

Similar Threads
Thread Thread Starter Forum Replies Last Post
Biogen acquires two ALS candidates lgelb ALS Research News 0 07-24-2018 03:54 PM
Biogen quits development of dexpramipexole for ALS edjohnson General Discussion About ALS/MND 11 01-06-2013 07:36 PM
Biogen quits development of dexpramipexole for ALS Sequoia ALS Research News 0 01-03-2013 12:30 PM
Let's all ask Biogen to Treat Us Now! Sequoia People With ALS - "PALS" 36 02-26-2012 10:34 PM
Biogen drug development with Knopp Ghost Dancer ALS Research News 8 01-11-2011 09:33 PM


All times are GMT -5. The time now is 11:23 PM.

 

Who we are

"We are a volunteer-driven online community that originated in 2003. We are a resource for anyone affected by ALS and MND. We are a community of like-minded and compassionate individuals. Together we are the ALS Forum and together we build this online resource and online community."

 

Want to help?

Have you found our website helpful? Do you enjoy having a place to talk to people that are knowledgeable about ALS and MND? If you have found it helpful to chat with people at different stages of the ALS/MND journey we encourage you to get involved.

Copyright © 2016